ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.

Abstract

Twenty-seven patients with advanced adenocarcinoma of the endometrium were accessioned into this Phase II study evaluating the efficacy of ICRF-159 (razoxane) as second-line chemotherapy between February 1981 and September 1983. One patient was ineligible because of an undocumented primary. One patient was invaluable because of concurrent use of adjunctive therapy and one patient had an inadequate trial. Twenty-four evaluable patients with measurable disease were given ICRF-159 orally at a starting dose of 1.5 g/m2 weekly until response could be determined. Grade 4 hematologic adverse effects were the only significant toxicity. There was no evidence of tumor response in any of the patients. Fourteen patients had stable disease and 10 had progressive disease. No activity was noted in advanced adenocarcinoma of the endometrium with ICRF-159 administered in the above dose and schedule.

• Authors: H D Homesley, J A Blessing, J Conroy, K Hatch, P J DiSaia, L B Twiggs
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 9 Issue 1 Pg. 15-7 (Feb 1986) ISSN: 0277-3732 [Print] United States
• PMID: 3953488 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Piperazines
• Razoxane

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Piperazines (therapeutic use)
• Razoxane (therapeutic use)
• Uterine Neoplasms (drug therapy)